trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 'lung', 'destiny,lung02', 'destiny,lung01']
key toxicity is interstitial lung disease (ild) and in destiny-lung02, ild rate lower at the 5.4mg/kg dose (6% overall, 1% g3) than the 6.4mg/kg dose (14% - also lower than the 26% seen in destiny-lung01). quicker onset at higher dose #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him